Physician profile
Alejandro Vasquez
NPI 1164493367
$44,849.90
in general payments reported to CMS, 2019-2025
34 companies · $5,394 in 2025
The $5,394 reported for 2025 was more than what 84% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $10K · 2021: $5,913 · 2022: $2,325 · 2023: $1,173 · 2024: $3,047 · 2025: $5,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $4,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $4,613.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $34,105.45 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $3,532.45 | 2019-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Rotapro |
| Abbott Laboratories | $2,015.69 | 2019-2025 | Navitor, Optis, Amplatzer Amulet |
| Medtronic, INC. | $841.57 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Hawkone |
| Novartis Pharmaceuticals Corporation | $749.60 | 2019-2025 | |
| Pfizer INC. | $685.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $468.46 | 2019-2024 | Xarelto |
| Amgen INC. | $380.12 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $351.96 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $305.84 | 2019-2022 | |
| Novo Nordisk INC | $235.96 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic Vascular, INC. | $168.25 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.22 | 2019-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $124.44 | 2019-2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $122.38 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $109.00 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.36 | 2022-2025 | Lifevest |
| Abiomed | $81.03 | 2025 | |
| Cardiovascular Systems INC. | $78.92 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.94 | 2020-2025 | |
| Esperion Therapeutics, INC. | $28.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.75 | 2025 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $22.85 | 2019 | |
| Siemens Medical Solutions USA, INC. | $18.36 | 2019 | |
| Scpharmaceuticals INC. | $17.92 | 2024 | |
| Recor Medical INC | $15.96 | 2025 | Paradise Ultrasound Renal Denervation System |
| Alnylam Pharmaceuticals INC. | $15.73 | 2025 | Amvuttra |
| Gilead Sciences, INC. | $13.87 | 2019 | |
| Atricure, INC. | $13.07 | 2023 | |
| Philips North America LLC | $11.51 | 2021 | |
| Chiesi USA, INC. | $11.21 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.